ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses1.4 M-223 K1.22 M787 K957 K2.74 MResearch & development57 K-664 K————Operating income1.46 M1.02 M253 K885 K624 K2.78 MNon-Operating Income, Total47 K65 K100 K123 K156 K444 KInterest expense, net of interest capitalized1 0001 000————Non-Operating Income, excl. Interest Expenses47 K65 K100 K123 K156 K444 KUnusual income/expense-1 000-1 000————Pretax income1.5 M1.08 M353 K1.01 M780 K3.22 MEquity in earnings——————Taxes——————Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations1.41 M952 K153 K762 K468 K2.33 MDiscontinued operations——————Net income1.41 M952 K153 K762 K468 K2.33 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders1.41 M952 K153 K762 K468 K2.33 MBasic earnings per share (Basic EPS)-26.56-0.05-0.19-0.076.25Diluted earnings per share (Diluted EPS)-26.56-0.05-0.19-0.076.25Average basic shares outstanding736.81 K609.7 K2.86 M4.02 M6.24 M13.73 MDiluted shares outstanding736.81 K609.7 K2.86 M4.02 M6.24 M13.73 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)100 K80 K34 K00114 K
Mustang Bio Inc
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency.